FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of formula (Ie) or pharmaceutically acceptable salts thereof: where Z is NR7R8 or S(O)aR7, where a is 0; R1 is H or C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxyl, C1-C6 alkoxy; Each of R2 and R4 is independently -Q1-T1, wherein Q1 is a bond or a C1-C3 alkyl linker optionally substituted with one or more substituents selected from halogen and hydroxyl, and T1 is H, C1-C3 alkyl; R3 is H or halogen; R5 is H or C1-C6 alkyl; R6 is H, halogen, -C(O)NRaRb or RS2, where RS2 is C1-C6 alkyl or 4-12 membered heterocycloalkyl containing from 0 to 3 heteroatoms in the ring selected from O, N or S, and Wherein each of Ra and Rb is independently H, C1-C6 alkyl or Ra and Rb together with the N atom to which they are attached form a 4-12 membered heterocycloalkyl ring containing 0 or 1 additional heteroatom selected from O, N or S; R7 is -Q4-T4, wherein Q4 is a bond or a C1-C4 alkyl linker and T4 is H, C1-C6 alkyl, C3-C8 cycloalkyl, C(O)-C1-C6 alkyl or 4-14 membered heterocycloalkyl, Containing 1 to 3 ring heteroatoms selected from O, N or S, each of which is optionally substituted with one or more -Q5-T5, wherein Q5 is a bond, C(O), C(O) NRk, NRkC(O) or a C1-C3 alkyl linker, wherein Rk is H or C1-C6 alkyl, and T5 is H, C1-C6 alkyl; R8 is H, C1-C6 alkyl optionally substituted with halogen or C1-C6 alkoxy, C2-C6 alkenyl, C3-C8 cycloalkyl or 4- to 7-membered heterocycloalkyl containing 1-3 heteroatoms in the ring selected from O, N or S; or R7 and R8 together with the N atom to which they are attached form a 4-12 membered heterocycloalkyl ring containing 0-2 additional heteroatoms selected from O, S or N and a 4-12 membered heterocycloalkyl ring that forms R7 and R8 is optionally substituted with one or more -Q6-T6, wherein Q6 is a bond or a C1-C3 alkyl linker and T6 is H, halogen, C1-C6 alkyl; and R12 is halogen, C1-C6 alkoxyl, C2-C6 alkenyl or C1-C6 alkyl optionally substituted with halogen.
EFFECT: compounds are used to treat cancer.
24 cl, 4 tbl, 47 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2632193C2 |
TREATMENT METHOD | 2012 |
|
RU2621148C2 |
1,3-BENZODIOXOLE DERIVATIVE | 2015 |
|
RU2679131C2 |
PYRIDINONE COMPOUNDS AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV-INFECTED CELLS | 2020 |
|
RU2816090C2 |
TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID-DEHYDROGENASE 1 | 2009 |
|
RU2539979C2 |
PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | 2011 |
|
RU2617405C2 |
NOVEL COMPOUNDS | 2001 |
|
RU2419608C2 |
DERIVATIVES OF PIPERIDINE, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2298550C2 |
Authors
Dates
2017-08-24—Published
2012-04-13—Filed